CAR immune cells: design principles, resistance and the next generation
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CAR immune cells: design principles, resistance and the next generation
Authors
Keywords
-
Journal
NATURE
Volume 614, Issue 7949, Pages 635-648
Publisher
Springer Science and Business Media LLC
Online
2023-02-23
DOI
10.1038/s41586-023-05707-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Leveraging biomaterials for enhancing T cell immunotherapy
- (2022) Ziyan Liao et al. JOURNAL OF CONTROLLED RELEASE
- Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
- (2022) J. Joseph Melenhorst et al. NATURE
- GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
- (2022) Robbie G. Majzner et al. NATURE
- HLA-independent T cell receptors for targeting tumors with low antigen density
- (2022) Jorge Mansilla-Soto et al. NATURE MEDICINE
- CAR T cells produced in vivo to treat cardiac injury
- (2022) Joel G. Rurik et al. SCIENCE
- Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells
- (2022) Talar Tokatlian et al. Journal for ImmunoTherapy of Cancer
- Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia
- (2022) Mark B. Leick et al. CANCER CELL
- Enhanced safety and efficacy of protease-regulated CAR-T cell receptors
- (2022) Louai Labanieh et al. CELL
- Modular design of synthetic receptors for programmed gene regulation in cell therapies
- (2022) Iowis Zhu et al. CELL
- 3D-organoid culture supports differentiation of human CAR+ iPSCs into highly functional CAR T cells
- (2022) Zhiqiang Wang et al. Cell Stem Cell
- Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
- (2022) Mingzhi Zhang et al. CLINICAL CANCER RESEARCH
- CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours
- (2022) Rebecca C. Larson et al. NATURE
- Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
- (2022) Changsong Qi et al. NATURE MEDICINE
- PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial
- (2022) Vivek Narayan et al. NATURE MEDICINE
- Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial
- (2022) Sattva S. Neelapu et al. NATURE MEDICINE
- Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
- (2022) Thomas Martin et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1 study of ADI-001: Anti-CD20 CAR-engineered allogeneic gamma delta (γδ) T cells in adults with B-cell malignancies.
- (2022) Sattva Swarup Neelapu et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 study of CART-ddBCMA in relapsed or refractory multiple myeloma.
- (2022) Matthew J. Frigault et al. JOURNAL OF CLINICAL ONCOLOGY
- Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
- (2022) Manali Kamdar et al. LANCET
- Potentiating adoptive cell therapy using synthetic IL-9 receptors
- (2022) Anusha Kalbasi et al. NATURE
- Antigen glycosylation regulates efficacy of CAR T cells targeting CD19
- (2022) Amanda Heard et al. Nature Communications
- Screening for CD19-specific chimaeric antigen receptors with enhanced signalling via a barcoded library of intracellular domains
- (2022) Khloe S. Gordon et al. Nature Biomedical Engineering
- CD58 loss in tumor cells confers functional impairment of CAR T cells
- (2022) Xin Yan et al. Blood Advances
- High-performance multiplex drug-gated CAR circuits
- (2022) Hui-Shan Li et al. CANCER CELL
- Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL
- (2022) Jiqin Zhang et al. NATURE
- High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails
- (2022) Brian R. Shy et al. NATURE BIOTECHNOLOGY
- Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy
- (2022) Zinaida Good et al. NATURE MEDICINE
- Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma
- (2022) Nicholas J. Haradhvala et al. NATURE MEDICINE
- Interleukin-18 Secreting Autologous Anti-CD19 CAR T-Cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-Cell Therapy
- (2022) Jakub Svoboda et al. BLOOD
- Enhanced T cell effector activity by targeting the Mediator kinase module
- (2022) Katherine A. Freitas et al. SCIENCE
- Decoding CAR T cell phenotype using combinatorial signaling motif libraries and machine learning
- (2022) Kyle G. Daniels et al. SCIENCE
- Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies
- (2022) Daniel B. Goodman et al. Science Translational Medicine
- Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide
- (2021) Max Jan et al. Science Translational Medicine
- Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma
- (2021) Giulia Agliardi et al. Nature Communications
- Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma
- (2021) Matteo C. Da Vià et al. NATURE MEDICINE
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- (2021) Nikhil C. Munshi et al. NEW ENGLAND JOURNAL OF MEDICINE
- T cell circuits that sense antigen density with an ultrasensitive threshold
- (2021) Rogelio A. Hernandez-Lopez et al. SCIENCE
- Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
- (2021) Mehmet Kemal Samur et al. Nature Communications
- A chimeric GM-CSF/IL18 receptor to sustain CAR T-cell function
- (2021) Shannon Lange et al. Cancer Discovery
- Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling
- (2021) Elisa Landoni et al. Cancer Immunology Research
- Investigation of product derived lymphoma following infusion of piggyBac modified CD19 chimeric antigen receptor T-cells
- (2021) Kenneth Paul Micklethwaite et al. BLOOD
- Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL
- (2021) Nirali N. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells
- (2021) Nathan Singh et al. NATURE MEDICINE
- Genetic in vivo engineering of human T lymphocytes in mouse models
- (2021) Tatjana Weidner et al. Nature Protocols
- Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
- (2021) Evan W. Weber et al. SCIENCE
- SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models
- (2021) Axel Hyrenius-Wittsten et al. Science Translational Medicine
- Trispecific CD19-CD20-CD22–targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models
- (2021) Dina Schneider et al. Science Translational Medicine
- Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors
- (2021) Yue Liu et al. Science Translational Medicine
- Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells
- (2021) Bo Wang et al. Nature Biomedical Engineering
- CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel
- (2021) Vicki Plaks et al. BLOOD
- The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function
- (2021) Lexus R. Johnson et al. CELL
- Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming
- (2021) Federico Simonetta et al. CLINICAL CANCER RESEARCH
- Efficient killing of tumor cells by CAR-T cells requires greater number of engaged CARs than TCRs
- (2021) Nadia Anikeeva et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial
- (2021) Jing Pan et al. JOURNAL OF CLINICAL ONCOLOGY
- Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial
- (2021) Matthew J. Frank et al. JOURNAL OF CLINICAL ONCOLOGY
- CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
- (2021) Qingya Cui et al. Journal of Hematology & Oncology
- KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
- (2021) Bijal D Shah et al. LANCET
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
- (2021) Jesus G Berdeja et al. LANCET
- Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial
- (2021) Yajing Zhang et al. LEUKEMIA
- BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells
- (2021) Hyungseok Seo et al. NATURE IMMUNOLOGY
- CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
- (2021) Jay Y. Spiegel et al. NATURE MEDICINE
- Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis
- (2021) Nicholas A. Vitanza et al. NATURE MEDICINE
- CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
- (2021) Dimitrios Mougiakakos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function
- (2021) Alexander I. Salter et al. Science Signaling
- Rationally Designed Transgene-Encoded Cell-Surface Polypeptide Tag for Multiplexed Programming of CAR T-cell Synthetic Outputs
- (2021) Adam J. Johnson et al. Cancer Immunology Research
- Control of the activity of CAR-T cells within tumours via focused ultrasound
- (2021) Yiqian Wu et al. Nature Biomedical Engineering
- Engineered Hypoimmune Allogeneic CAR T Cells Exhibit Innate and Adaptive Immune Evasion Even after Sensitization in Humanized Mice and Retain Potent Anti-Tumor Activity
- (2021) Xiaomeng Hu et al. BLOOD
- First in Human Study of an on/Off Switchable CAR-T Cell Platform Targeting CD19 for B Cell Malignancies (CLBR001 + SWI019)
- (2021) Liana Nikolaenko et al. BLOOD
- CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy
- (2021) Matthew J. Frank et al. BLOOD
- High Effectiveness and Safety of Anti-CD7 CAR T-Cell Therapy in Treating Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)
- (2021) Junfang Yang et al. BLOOD
- SCRI-CAR19x22v2 T Cell Product Demonstrates Bispecific Activity in B-ALL
- (2021) Colleen Annesley et al. BLOOD
- Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma
- (2021) Veronika Bachanova et al. BLOOD
- Phase I First-in-Class Trial of MCARH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma
- (2021) Sham Mailankody et al. BLOOD
- GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity
- (2021) Sabine Heitzeneder et al. CANCER CELL
- An NK-like CAR T cell transition in CAR T cell dysfunction
- (2021) Charly R. Good et al. CELL
- Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer
- (2021) Andrew DJ. Pearson et al. EUROPEAN JOURNAL OF CANCER
- Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report
- (2021) Liora M. Schultz et al. JOURNAL OF CLINICAL ONCOLOGY
- Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
- (2021) Caron A Jacobson et al. LANCET ONCOLOGY
- Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs
- (2021) Mark Yarmarkovich et al. NATURE
- Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
- (2021) Nathan Hale Fowler et al. NATURE MEDICINE
- Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy
- (2021) Oliver Van Oekelen et al. NATURE MEDICINE
- CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial
- (2021) Shaun Cordoba et al. NATURE MEDICINE
- Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
- (2021) Frederick L. Locke et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence
- (2021) Afroditi Katsarou et al. Science Translational Medicine
- A human orthogonal IL-2 and IL-2Rβ system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia
- (2021) Qian Zhang et al. Science Translational Medicine
- Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity
- (2021) Brooke Prinzing et al. Science Translational Medicine
- Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients
- (2021) Michael Maschan et al. Nature Communications
- A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma
- (2020) Javier Munoz et al. BLOOD
- A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy
- (2020) Greta Giordano-Attianese et al. NATURE BIOTECHNOLOGY
- Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
- (2020) Jennifer N. Brudno et al. NATURE MEDICINE
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
- (2020) Enli Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- CRISPR-engineered T cells in patients with refractory cancer
- (2020) Edward A. Stadtmauer et al. SCIENCE
- Glypican-3–Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma
- (2020) Sai Arun Batra et al. Cancer Immunology Research
- Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability
- (2020) Sonia Guedan et al. JOURNAL OF CLINICAL INVESTIGATION
- CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
- (2020) Nirali N. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
- (2020) Loretta J. Nastoupil et al. JOURNAL OF CLINICAL ONCOLOGY
- Human chimeric antigen receptor macrophages for cancer immunotherapy
- (2020) Michael Klichinsky et al. NATURE BIOTECHNOLOGY
- Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity
- (2020) Junyun Lai et al. NATURE IMMUNOLOGY
- Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors
- (2020) Johanna Theruvath et al. NATURE MEDICINE
- Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma
- (2020) Laura K. Donovan et al. NATURE MEDICINE
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tuning the Antigen Density Requirement for CAR T-cell Activity
- (2020) Robbie G. Majzner et al. Cancer Discovery
- A Chemical Switch System to Modulate Chimeric Antigen Receptor T Cell Activity through Proteolysis-Targeting Chimaera Technology
- (2020) So Myoung Lee et al. ACS Synthetic Biology
- Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy
- (2020) Yuki Kagoya et al. Cancer Immunology Research
- Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold
- (2020) Kento Fujiwara et al. Cells
- Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity
- (2020) Huang Zhu et al. Cell Stem Cell
- Rewired signaling network in T cells expressing the chimeric antigen receptor ( CAR )
- (2020) Rui Dong et al. EMBO JOURNAL
- Chimeric Antigen Receptor Designed to Prevent Ubiquitination and Downregulation Showed Durable Antitumor Efficacy
- (2020) Wentao Li et al. IMMUNITY
- Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
- (2020) Carlos A. Ramos et al. JOURNAL OF CLINICAL ONCOLOGY
- Ligand-Induced Degradation of a CAR Permits Reversible Remote Control of CAR T Cell Activity In Vitro and In Vivo
- (2020) Sarah A. Richman et al. MOLECULAR THERAPY
- Senolytic CAR T cells reverse senescence-associated pathologies
- (2020) Corina Amor et al. NATURE
- Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors
- (2020) Andrew V. Anzalone et al. NATURE BIOTECHNOLOGY
- Metabolic engineering generates a transgene-free safety switch for cell therapy
- (2020) Volker Wiebking et al. NATURE BIOTECHNOLOGY
- Inefficient CAR-proximal signaling blunts antigen sensitivity
- (2020) Venugopal Gudipati et al. NATURE IMMUNOLOGY
- A conformation-specific ON-switch for controlling CAR T cells with an orally available drug
- (2020) Charlotte U. Zajc et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma
- (2020) Meenakshi Hegde et al. Nature Communications
- The CD28 Transmembrane Domain Contains an Essential Dimerization Motif
- (2020) Scott A. Leddon et al. Frontiers in Immunology
- Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B cell malignancies
- (2020) Jordan Gauthier et al. BLOOD
- Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies
- (2020) Jingwen Si et al. CANCER CELL
- A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients (pts) with MUC16ecto+ recurrent high-grade serous ovarian cancer (HGSOC)
- (2020) R.E. O'Cearbhaill et al. GYNECOLOGIC ONCOLOGY
- A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy
- (2020) Shannon K. Oda et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis
- (2020) Andras Heczey et al. NATURE MEDICINE
- Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
- (2020) Nirav N. Shah et al. NATURE MEDICINE
- Designed protein logic to target cells with precise combinations of surface antigens
- (2020) Marc J. Lajoie et al. SCIENCE
- CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma
- (2020) John H Baird et al. BLOOD
- CD4+ T cells engineered with FVIII-CAR and murine Foxp3 suppress anti-factor VIII immune responses in hemophilia a mice
- (2020) Richard Y. Fu et al. CELLULAR IMMUNOLOGY
- Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
- (2020) Reuben Benjamin et al. LANCET
- Antitumor activity without on-target off-tumor toxicity of GD2–chimeric antigen receptor T cells in patients with neuroblastoma
- (2020) Karin Straathof et al. Science Translational Medicine
- CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies
- (2020) Dongrui Wang et al. Cancer Discovery
- CAR T cells targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors
- (2019) Robbie G. Majzner et al. CLINICAL CANCER RESEARCH
- Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus
- (2019) Rita Kansal et al. Science Translational Medicine
- Proliferation tracing with single-cell mass cytometry optimizes generation of stem cell memory-like T cells
- (2019) Zinaida Good et al. NATURE BIOTECHNOLOGY
- NR4A transcription factors limit CAR T cell function in solid tumours
- (2019) Joyce Chen et al. NATURE
- CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
- (2019) Mohamad Hamieh et al. NATURE
- T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy
- (2019) Tori N. Yamamoto et al. JOURNAL OF CLINICAL INVESTIGATION
- Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting
- (2019) Shivani Srivastava et al. CANCER CELL
- Modulation of Target Antigen Density Improves CAR T Cell Functionality and Persistence
- (2019) Sneha Ramakrishna et al. CLINICAL CANCER RESEARCH
- B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
- (2019) Adam D. Cohen et al. JOURNAL OF CLINICAL INVESTIGATION
- CD19 CAR T cell product and disease attributes predict leukemia remission durability
- (2019) Olivia C. Finney et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
- (2019) Bryan D. Choi et al. NATURE BIOTECHNOLOGY
- TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion
- (2019) Hyungseok Seo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response
- (2019) Patrick A. Baeuerle et al. Nature Communications
- γ-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma
- (2019) Margot J. Pont et al. BLOOD
- Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells
- (2019) Matthew B. Dong et al. CELL
- Targeting cardiac fibrosis with engineered T cells
- (2019) Haig Aghajanian et al. NATURE
- PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity
- (2019) Martin W. LaFleur et al. NATURE IMMUNOLOGY
- Clinical lessons learned from the first leg of the CAR T cell journey
- (2019) Robbie G. Majzner et al. NATURE MEDICINE
- An AND-Gated Drug and Photoactivatable Cre-loxP System for Spatiotemporal Control in Cell-Based Therapeutics
- (2019) Molly E. Allen et al. ACS Synthetic Biology
- A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial
- (2019) Zhiling Yan et al. Lancet Haematology
- c-Jun overexpression in CAR T cells induces exhaustion resistance
- (2019) Rachel C. Lynn et al. NATURE
- Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy
- (2019) Jun Wei et al. NATURE
- CRISPR/Cas9-mediated knockout of DGK improves anti-tumor activities of human T cells
- (2018) In-Young Jung et al. CANCER RESEARCH
- Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
- (2018) Jang Hwan Cho et al. CELL
- T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
- (2018) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells
- (2018) Wenting Zheng et al. LEUKEMIA
- Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication
- (2018) Christopher C. Kloss et al. MOLECULAR THERAPY
- IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
- (2018) Keishi Adachi et al. NATURE BIOTECHNOLOGY
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
- (2018) Joseph A. Fraietta et al. NATURE MEDICINE
- Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas
- (2018) Christopher W. Mount et al. NATURE MEDICINE
- A novel chimeric antigen receptor containing a JAK–STAT signaling domain mediates superior antitumor effects
- (2018) Yuki Kagoya et al. NATURE MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259 T Cells in Synovial Sarcoma
- (2018) Sandra P. D'Angelo et al. Cancer Discovery
- Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System
- (2018) Mauro P. Avanzi et al. Cell Reports
- Chimeric antigen receptors that trigger phagocytosis
- (2018) Meghan A Morrissey et al. eLife
- Reducing Ex Vivo Culture Improves the Anti-leukemic Activity of Chimeric Antigen Receptor (CAR)-T Cells
- (2018) Saba Ghassemi et al. Cancer Immunology Research
- A phase I trial of T4 CAR T-cell immunotherapy in head and neck squamous cancer (HNSCC).
- (2018) Sophie Papa et al. JOURNAL OF CLINICAL ONCOLOGY
- Reprogramming human T cell function and specificity with non-viral genome targeting
- (2018) Theodore L. Roth et al. NATURE
- Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
- (2018) Joseph A. Fraietta et al. NATURE
- Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
- (2018) Sarwish Rafiq et al. NATURE BIOTECHNOLOGY
- Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
- (2018) Elena J. Orlando et al. NATURE MEDICINE
- Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function
- (2018) Alexander I. Salter et al. Science Signaling
- GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
- (2018) Rosalie M. Sterner et al. BLOOD
- Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function
- (2018) Eric Shifrut et al. CELL
- Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency
- (2018) Judith Feucht et al. NATURE MEDICINE
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and efficacy of Tet-regulated IL-12 expression in cancer-specific T cells
- (2018) Ahdab Alsaieedi et al. OncoImmunology
- A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release
- (2018) Yiyang Xu et al. Cell Discovery
- Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy
- (2017) Paul A. Beavis et al. JOURNAL OF CLINICAL INVESTIGATION
- Comparison of T Cell Activities Mediated by Human TCRs and CARs That Use the Same Recognition Domains
- (2017) Daniel T. Harris et al. JOURNAL OF IMMUNOLOGY
- Masked Chimeric Antigen Receptor for Tumor-Specific Activation
- (2017) Xiaolu Han et al. MOLECULAR THERAPY
- Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase
- (2017) Alec J. Walker et al. MOLECULAR THERAPY
- Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer
- (2017) Somala Mohammed et al. MOLECULAR THERAPY
- Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
- (2017) Justin Eyquem et al. NATURE
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
- (2017) Terry J Fry et al. NATURE MEDICINE
- In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers
- (2017) Tyrel T. Smith et al. Nature Nanotechnology
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
- (2017) Donald M. O’Rourke et al. Science Translational Medicine
- TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance
- (2017) Yinmeng Yang et al. Science Translational Medicine
- Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
- (2017) Waseem Qasim et al. Science Translational Medicine
- Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models
- (2017) Melinda Mata et al. Cancer Discovery
- Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
- (2017) Thomas Shum et al. Cancer Discovery
- A versatile system for rapid multiplex genome-edited CAR T cell generation
- (2017) Jiangtao Ren et al. Oncotarget
- Modularly Constructed Synthetic Granzyme B Molecule Enables Interrogation of Intracellular Proteases for Targeted Cytotoxicity
- (2017) Patrick Ho et al. ACS Synthetic Biology
- Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18
- (2017) Biliang Hu et al. Cell Reports
- Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants
- (2017) Giedre Krenciute et al. Cancer Immunology Research
- CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells
- (2017) Yongping Zhang et al. Frontiers of Medicine
- Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer
- (2017) Kristen M. Hege et al. Journal for ImmunoTherapy of Cancer
- A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
- (2016) Xiaojun Liu et al. CANCER RESEARCH
- Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells
- (2016) Michael Boice et al. CELL
- Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits
- (2016) Kole T. Roybal et al. CELL
- Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
- (2016) Jiangtao Ren et al. CLINICAL CANCER RESEARCH
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
- (2016) Omkar U. Kawalekar et al. IMMUNITY
- The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction
- (2016) Nicole E. Scharping et al. IMMUNITY
- Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
- (2016) Leonid Cherkassky et al. JOURNAL OF CLINICAL INVESTIGATION
- Clinical responses with T lymphocytes targeting malignancy-associated κ light chains
- (2016) Carlos A. Ramos et al. JOURNAL OF CLINICAL INVESTIGATION
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
- (2016) Cameron J. Turtle et al. JOURNAL OF CLINICAL INVESTIGATION
- Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
- (2016) Meenakshi Hegde et al. JOURNAL OF CLINICAL INVESTIGATION
- Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor
- (2016) Katherine G. MacDonald et al. JOURNAL OF CLINICAL INVESTIGATION
- Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism
- (2016) Wei Yang et al. NATURE
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
- (2016) Christine E. Brown et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells
- (2016) Lenka V. Hurton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
- (2016) Elad Jacoby et al. Nature Communications
- Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization
- (2016) K. Newick et al. Cancer Immunology Research
- A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration
- (2016) R. Sakemura et al. Cancer Immunology Research
- Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient
- (2016) Imran Siddiqui et al. Journal for ImmunoTherapy of Cancer
- Coexpressed Catalase Protects Chimeric Antigen Receptor–Redirected T Cells as well as Bystander Cells from Oxidative Stress–Induced Loss of Antitumor Activity
- (2015) Maarten A. Ligtenberg et al. JOURNAL OF IMMUNOLOGY
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression
- (2015) Kevin J Curran et al. MOLECULAR THERAPY
- Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes
- (2015) Ignazio Caruana et al. NATURE MEDICINE
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
- (2015) Adrienne H Long et al. NATURE MEDICINE
- Remote control of therapeutic T cells through a small molecule-gated chimeric receptor
- (2015) C.-Y. Wu et al. SCIENCE
- Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
- (2015) E. Sotillo et al. Cancer Discovery
- Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15
- (2014) Y. Xu et al. BLOOD
- Antigen Sensitivity of CD22-Specific Chimeric TCR Is Modulated by Target Epitope Distance from the Cell Membrane
- (2014) S. E. James et al. JOURNAL OF IMMUNOLOGY
- Target Antigen Density Governs the Efficacy of Anti–CD20-CD28-CD3 ζ Chimeric Antigen Receptor–Modified Effector CD8+T Cells
- (2014) Keisuke Watanabe et al. JOURNAL OF IMMUNOLOGY
- Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells
- (2013) M. Hudecek et al. CLINICAL CANCER RESEARCH
- Chimeric γc cytokine receptors confer cytokine independent engraftment of human T lymphocytes
- (2013) Michelle R. Hunter et al. MOLECULAR IMMUNOLOGY
- Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma
- (2013) Sunitha Kakarla et al. MOLECULAR THERAPY
- Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
- (2013) Cor HJ Lamers et al. MOLECULAR THERAPY
- Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy
- (2013) Maria Themeli et al. NATURE BIOTECHNOLOGY
- PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses
- (2013) V. D. Fedorov et al. Science Translational Medicine
- Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
- (2012) W. Haso et al. BLOOD
- Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
- (2012) Christopher C Kloss et al. NATURE BIOTECHNOLOGY
- Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
- (2012) J. Scholler et al. Science Translational Medicine
- A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells
- (2011) X. Wang et al. BLOOD
- Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
- (2011) C. U. Louis et al. BLOOD
- Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
- (2011) R. J. Brentjens et al. BLOOD
- CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients
- (2011) Barbara Savoldo et al. JOURNAL OF CLINICAL INVESTIGATION
- Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
- (2011) Paul F. Robbins et al. JOURNAL OF CLINICAL ONCOLOGY
- Improving Adoptive T Cell Therapy by Targeting and Controlling IL-12 Expression to the Tumor Environment
- (2011) Ling Zhang et al. MOLECULAR THERAPY
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
- (2010) J. N. Kochenderfer et al. BLOOD
- The Optimal Antigen Response of Chimeric Antigen Receptors Harboring the CD3 Transmembrane Domain Is Dependent upon Incorporation of the Receptor into the Endogenous TCR/CD3 Complex
- (2010) J. S. Bridgeman et al. JOURNAL OF IMMUNOLOGY
- Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b
- (2010) John A. Craddock et al. JOURNAL OF IMMUNOTHERAPY
- T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model
- (2009) A. Di Stasi et al. BLOOD
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
- (2009) Michael C. Milone et al. MOLECULAR THERAPY
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
- (2008) Martin A Pule et al. NATURE MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started